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Computational Estimation of Fetal DNA Fraction in Low Coverage 
Whole Genome Sequencing Data 
Abstract: 
The aim of this thesis was to find and ‘calibrate’ computational methodology for estimat-
ing the proportion of cell-free fetal DNA (cffDNA) in pregnant women’s blood sample. 
This work was done as part of an applied research project aimed to develop a whole ge-
nome sequencing (WGS) based non-invasive prenatal testing (NIPT) medical screening 
test. NIPT is the most up-to-date, accurate and easily applied (non-invasive) prenatal 
screening method to detect fetal aneuploidies (for example trisomy 21, that causes Down 
syndrome) with high confidence and already during the first trimester of pregnancy. 
Commonly, NIPT is based on the low coverage WGS data, generated by the means of Il-
lumina or some another platform technology. Computational tools used for aneuploidy 
detection can also estimate the proportion of cffDNA in maternal blood for both male and 
female fetus pregnancies. Fetal fraction calculation is a prerequisite to assure the technical 
credibility of NIPT screening test. In the current study, low coverage cell-free whole ge-
nome sequencing data from 416 pregnant women were used to develop a chromosome Y 
based estimator for the proportion of cffDNA in male-fetus pregnancy cases. Next, the 
chromosome Y based estimator was used to validate the credibility of SeqFF computa-
tional method with Estonian NIPT samples. This developed approach using SeqFF method 
on Estonian NIPT samples enables to estimate the proportion of cffDNA in both male and 
female fetus pregnancies. The SeqFF method is now integrated into the NIPT computation 
workflow service, validated and in daily practical use as part of the NIPTIFY® screening 
test. 
Keywords: 
Cell-free fetal DNA, genome informatics, sequencing informatics, machine learning, elas-
tic net, chromosome Y based method, NIPT, fetal fraction 
CERCS: B110 Bioinformatics, medical informatics, biomathematics, biometrics 
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Loote DNA osahulga arvutamine madala katvusega täisgenoomi 
sekveneerimisandmetest 
Lühikokkuvõte: 
Käesoleva töö eesmärk oli leida ja kalibreerida arvutuslik metoodika loote rakuvaba DNA 
fraktsiooni määramiseks raseda naise vereproovis. Tegemist on rakendusliku teadusuurin-
guga, mis on eeltingimuseks NIPT testi usaldusväärseks rakendamiseks tervishoiusüstee-
mis. NIPT on kõige täpsem ja kaasaegsem mitteinvasiivne loote sünnieelne kromosoomi-
haiguste sõeluuring, mis põhineb madala katvusega täisgenoomi sekveneerimisandmete 
analüüsil. Metoodika võimaldab määrata loote rakuvaba DNA hulka raseda naise ve-
reproovis nii poiss- kui ka tüdruklootele, mis on vajalik, et iga raseduse rakuvaba DNA 
analüüsi tulemus oleks usaldusväärne ja arstile ning patsiendile edastatud tulemus tõene. 
Käesolevas töös kasutati madala katvusega üle-genoomsetest Illumina platvormiga läbi-
viidud sekveneerimise katsetest saadud 416 Eesti päritolu naise NIPT proove, et välja töö-
tada Y-kromosoomi põhine loote rakuvaba DNA hulga määramine poiss-loodetele. Välja 
töötatud Y-kromosoomi põhist meetodit kasutati SeqFF arvutusliku metoodika valideeri-
miseks Eesti NIPT proovidel. SeqFF rakendamine Eesti NIPT proovidel võimaldab määra-
ta loote rakuvaba DNA hulka nii poiss- kui ka tüdrukloodetel. Väljatöötatud algoritm on 
integreeritud Eestis pakutavasse NIPT täppismeditsiini teenusesse NIPTIFY. 
Võtmesõnad: 
Loote rakuvaba DNA, NIPT, genoomi informaatika, sekveneerimise informaatika, SeqFF, 
masinõpe, elastic net, Y-kromosoomi põhine meetod loote rakuvaba DNA hulga määrami-
seks 
CERCS: B110 Bioinformaatika, meditsiiniinformaatika, biomatemaatika, biomeetrika 
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 Introduction 
Currently, prenatal testing during the first and second trimester of pregnancy is applied as 
routine screening method to detect possible fetus chromosomal disease risk as early as 
possible. Such screening is reimbursed and provided for all pregnant women in Estonia. 
Currently used serum and ultrasound biomarker-based screening test, combined with inva-
sive diagnostic tests reveal around 30 Down syndrome (trisomy 21) fetuses annually 
(Figure 1) [1]. This is approximately 0.4–0.5% of all live births in Estonia. In addition to 
detected chromosomal diseases, around 5 Down syndrome children are born (most of them 
have left undetected) by currently used routine screening method annually [1]. Aneu-
ploidies like trisomy of chromosomes 13, 18 and 21, lead to a genetic disorder which ends 
with either a child's early death or a long-lasting mental and physical disability [2]. Alter-
native to current reimbursed screening method is more accurate non-invasive prenatal 
testing (NIPT) method that analyses the fragments of cell-free fetal DNA (cffDNA), 
which enters the maternal bloodstream mainly from placenta during the pregnancy [3] but 
disappear completely in a few days after delivery [4]. NIPT is currently the most accurate 
and sensitive noninvasive prenatal screening method that is already reimbursed for all 
women in some European countries like Belgium and Netherlands. 
 
Figure 1. Down's syndrome cases per 10,000 pregnancies/births and the outcome of ap-
plied prenatal screening since 2000. Figure illustrates how the number (y-axis) of the 
detection (grey line) of Down's syndrome has changed in recent years (x-axis). Red line 
illustrates the number of births with Down's syndrome and black line pre-birth cases. Fig-
ure modified from [1]. 
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NIPT enables to detect the loss or gain of fetal chromosomes directly based on cell-free 
fetal DNA analysis. Over- or underrepresented amount of cffDNA as compared to mater-
nal cell-free DNA indicates the altered chromosomal copy-number of fetus [3]. Such 
anomalies, including entire or partial chromosome loss or gain can be assessed with quan-
titative analysis of next-generation sequencing assays. Although NIPT is highly accurate, 
it is not currently meant for diagnostic purposes due to the fact that cffDNA has placental 
origin and the fetal DNA is mixed with maternal DNA. Those limitations may cause false 
positive or false negative results due to technical or biological reasons [3]. 
To ensure the maximum possible trustworthiness of NIPT, the estimation of fetal origin 
cffDNA percentage, fetal fraction (FF), among analyzed maternal sample is required [5].  
It is critical to determine the presence and proportion of fetal fraction to assure high-
quality and confident results that can be then reported back to the clinic. Missing fetal 
fraction but also very low cffDNA cases should be caught and handled appropriately (e.g. 
repeated test) to avoid low-quality and uncertain analysis results that can lead to false 
positive (incorrectly detected and reported chromosomal aneuploidy) and false negative 
results. False negative means that the analyzed sample has chromosomal aneuploidy (an 
extra disease-causing chromosome), but the test has failed to detect it. 
Our wet-lab and computational scientists at the Competence Centre on Health Technology 
have developed and validated WGS-based NIPT in Estonia [6]. This NIPT screening test, 
branded as NIPTIFY1 is available in more than 20 clinics across Estonia [7]. At its com-
putational core this test applies NIPTmer [6] k-mer-based software for detecting fetal 
aneuploidies from sequencing data [8]. Previously, we have demonstrated that although 
computationally superior to read mapping based approaches, k-mer counting based 
NIPTmer may give false negative results if FF is under 4% threshold [8]. Therefore, 
accurately knowing the FF of each analyzed sample is crucial for NIPT.  
The purpose of this thesis was to find and calibrate a suitable computational method-
ology for accurate estimation of fetal DNA fraction in NIPT. The estimation is based 
on very low, mean coverage 0.3–0.5× whole genome sequencing data and herein described 
approach is applied to NIPTIFY medical service.  
  
                                                 
1 http://www.niptify.ee 
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1.1 Existing computational methods for FF calculation 
Several computational methods have been developed for estimating fetal DNA fraction. 
First, a direct method to assess the fetal DNA fraction is single nucleotide variation based 
approach [9] [10]. This method requires availability of parental genotypes [9]. When pa-
rental genotypes are known, fetal-specific (paternally inherited) alleles in maternal plasma 
can be identified and the genotype ratio of fetal-specific alleles to the total alleles can be 
quantified [9]. The drawback of this approach is the requirement of parental genotypes 
that needs additional laboratory procedures and therefore considerably increases the price 
of NIPT [9]. 
Another method is methylation biomarker-based approach. A methyl group is a chemical 
‘label’ that is added to DNA cytosine nucleotides to regulate gene expression [9]. Differ-
ent organs and tissues have variable methylation patterns, which allows to identify the 
tissue of origin by the quantification of methylated cytosines in studied sample [9]. More 
precisely, human placenta has a different methylation profile as compared to the other cell 
types represented in maternal blood sample, allowing to estimate the FF of the studied 
sample [9]. However, the protocol of this method is currently considered too labor-
extensive and expensive for routine NIPT [9]. 
A third method is based on the fact that fetal origin cell-free DNA (cfDNA) fragments are 
about 20 bp shorter than the fragments of maternal cfDNA [9][11]. This allows to associ-
ate the proportion of shorter DNA fragments with the level of fetal fraction. The limitation 
of this method is that the corresponding assay requires relatively long sequencing reads to 
detect the DNA fragment length differences and that increases the experimental cost of 
routine NIPT [9]. 
Fourth method is based on the usage of chromosome Y specific sequencing reads, more 
specifically, its sequencing read count. Chromosome Y includes regions which are inherit-
ed uniparentally from father and are highly unique as compared to the rest of the genomic 
DNA sequences [9]. The ratio of these paternally inherited sequencing reads from chro-
mosome Y to the rest of the autosomal chromosomes can be calculated and interpreted as 
the estimate of the fetal fraction. Consequently, this method can be used only in case of 
male fetuses pregnancies [9]. On the other hand, it is also important to note that even in 
case of a female fetus pregnancy, some reads align to some parts of the chromosome Y 
due to highly identical sequences between Y and other chromosomes [5].  
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One such chromosome Y based method is DEFRAG [5]. DEFRAG calculates FF in the 
following way:  
DEFRAG =  
%𝑌𝑋𝑌 𝑓𝑒𝑡𝑢𝑠−%𝑌𝑋𝑋 𝑓𝑒𝑡𝑢𝑠
%𝑌𝑋𝑌 𝑚𝑎𝑛
,  
where %𝑌𝑋𝑌 𝑓𝑒𝑡𝑢𝑠 refers to the percentage of reads that align to the Y chromosome, 
%𝑌𝑋𝑌 𝑚𝑎𝑛 refers to the male control samples aligning to Y and %𝑌𝑋𝑋 refers to the female 
fetus pregnancy that align to the chromosome Y at 0% male DNA [5].  
Finally, a method that does not require parental genotype data and is not limited to male 
fetus pregnancies, is SeqFF, a machine learning based method for estimating fetal DNA 
fraction (FF) [12]. SeqFF uses the sequencing read data across all chromosomes and cal-
culates an average FF based on elastic net (Enet) and weighted rank selection criterion 
(WRSC) predictions as FF [12]. The input features for these models are the number of 
reads in bins (chromosomes are divided into regions, bins, with fixed length) over the 
whole genome, except chromosomes 13, 18, 21, X and Y [12]. 
The elastic net, a regularized regression, can be interpreted as a stabilized version of the 
lasso [13]. The elastic net penalty is a combination of the lasso and ridge penalty and have 
the characteristics of both the lasso and ridge regression [13]. Elastic net performs by find-
ing first the ride regression coefficients, followed by lasso-type shrinkage and finally cor-
recting extra bias from double shrinkage by rescaling coefficients [13]. The authors of the 
elastic net have shown empirically that elastic net outperforms lasso and ridge regression 
[13]. Moreover, elastic net performs well in cases where the number of features exceeds 
the number of available samples in the training set (which is the problem that SeqFF is 
trying to solve) [12][13].  
In WRSC, the individual bin values for chromosome Y are predicted using Reduced-Rank 
Regression [12]. Then, for both genders, chromosome representations are evaluated as the 
ratios of normalized chromosome X and Y read counts against the total autosomal read 
counts [12] [14]. Authors of SeqFF kindly made their trained model available for others to 
use [12]. It was trained on 25,312 pregnant women (with known fetal fraction) and further 
validated on 505 pregnant samples [12].  
Furthermore, literature has shown that SeqFF has been applied to pregnancies screened in 
Denmark [15], Netherlands [16] and United Kingdom [17]. First, Hartwig and the col-
leagues established an open source platform for NIPT based on massively parallel whole 
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genome sequencing in a public setting, where they used SeqFF for estimating the propor-
tion of cffDNA [15]. In their study, which was based on 165 randomly selected normal 
(euploid) pregnancies and 108 aneuploid cases, the authors also underlined the importance 
of FF as a NIPT quality parameter [15]. Second, there was a study, which aimed to deter-
mine the ‘gold standard’ method for the validation of FF estimators (using 3,847 pregnan-
cies) [17]. Their benchmark method indicated that SeqFF was the most  accurate method 
for estimating FF [17].  
To conclude this section, due to the availability of the trained model and its capability to 
estimate fetal fraction in both male and female fetus pregnancies, SeqFF method was cho-
sen. If validated on Estonian NIPT samples, SeqFF could prove reliable approach to esti-
mate fetal fraction for both boy and girl fetus pregnancies. 
1.2 Outline 
Used data and the development of computational methods describes the samples used, 
presents data processing pipeline, presents parameters that in different tools were used and 
gives detailed steps of developing chromosome Y based method (including chromosome 
Y region selection). Also, the optimization steps are presented with the setup of SeqFF. 
Discussion includes a brief summary, limitation and implications of the results. The future 
directions of related work are also presented. 
Results present description of the outcomes using the methods specified in the chapter 
‘Used data and the development of computational methods’. 
Summary gives a short overview of the thesis with results achieved. 
It is expected from the reader to know the terminology covered by the Master’s program 
of Computer Science and some basic terminology of biology. 
1.3 Author’s contribution 
The author developed the computational method for calculating fetal fraction using chro-
mosome Y. Development of the method included analysis of chromosome Y regions and 
selection of effective regions for the estimations, development of the formula (4) (Section 
2.8, page 25), creation of the analysis pipeline, finding the optimal parameters for each 
10 
processing step and the tools used and validation of the created method. Developed source 
code is available on GitHub2.  
Although SeqFF is a published method, it was not known if it would be applicable and 
give accurate results with our very low coverage WGS NIPT samples (generated by slight-
ly different laboratory protocol as in the original SeqFF study). The author of the current 
study also set up SeqFF and validated it against the previously developed chromosome Y 
based method. 
                                                 
2 https://github.com/PriitPaluoja/FetalFraction  
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 Used data and the development of computational methods 
The data used in the current study and developed methods are presented in detail below. 
2.1 Sample origin 
In total, 431 pregnant women blood samples were collected at collaborating clinical labor-
atories at the Tartu University Hospital and at the East-Tallinn Central Hospital. In the 
current thesis, 416 samples were used. Mean age of participants was 33 years, the collec-
tion included 209 male and 186 female fetus pregnancies. The rest were not defined in our 
dataset. These samples were sequenced by Illumina NextSeq 500 platform with an average 
coverage3 of 0.32× producing 85 bp single-end reads [6]. The study was approved by Re-
search Ethics Committee of the University of Tartu (#246/T-21) and written informed 
consent was obtained from all participants [6]. 
2.2 Sequencing data files 
Each sequenced sample had four files that had been sequenced on four lanes (Section 2.4). 
In compressed form, each FASTQ file was in average of 301.2 MB, concatenating all four 
files resulted in average of 1207.3 MB. After decompression and aligning to reference 
genome, the per-sample file size was in average 4.0 GB, which after mapping-quality 
based filtering was reduced to 2.7 GB. Input, a human readable text file (read counts in 
bins over the genome), for chromosome Y based method was in average of 326.7 MB.  
Based on the previous, the total size of processed data in concatenation step is 501.2 GB, 
in alignment step 1.7 TB, in mapping quality filtering 1.1 TB and for chromosome Y 
based method in total of 136 GB. In conclusion, at least 3.4 TB of data is analysed (Figure 
2) if fetal fraction is calculated for all the samples.  
3.4 TB of analysed data equals to a single run of the pipeline (Section 2.4) for all the sam-
ples, but during the development of the solution, many of these steps had to be done mul-
tiple times. For example, trying different quality parameters in filtering would lead to pro-
cessing and creation of several filtered files. The actual amount of data analysed during the 
development exceeds 3.4 TB. 
                                                 
3 The number of times each nucleotide is expected to be sequenced on average [26]. 
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Figure 2. Overview of the amount of data processed in single run of the pipeline. 
Alignment of reads against human genome surpasses all the other steps in the pipeline in 
terms of amount of data processed. 
In terms of read counts, over 385 files mapped to human reference genome, in average had 
≈ 14 × 106 reads. Overall, we can approximate the total number of reads mapped ≈
6 × 109. 
In conclusion, the development of the method for estimating fetal fraction on Estonian 
NIPT samples is in nature computational as it requires the analysis of over 3.4 TB of data 
or over 6 × 109 mapped reads. 
2.3 Parameters of sequencing reads alignment  
Sequencing reads were aligned (‘mapped’) to human reference genome sequence with 
Bowtie 2 (2.3.4.1) [18]. Bowtie 2 has combinations of parameters that are included into 
the shorter predetermined parameters [19]. The --very-sensitive option was used as it was 
also used in the SeqFF [12]. This option optimizes sensitivity over speed, which is pre-
ferred as in the development phase the speed of the analysis is less important than the ac-
curate results. More specifically, this option means that up to 20 consecutive seed exten-
sion attempts are tried do produce a new best alignment for each sequencing read before 
Bowtie 2 moves on [19]. Also, the maximum of three times will the Bowtie 2 choose a 
new set of reads at different offsets to find more alignments [19]. The function governing 
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the interval between seed substrings is set as of type square-root, with constant term 1 and 
coefficient of 0.50: 𝑓(𝑥) = 1 +  0.5 ⋅ √𝑥 [19]. 
Version GRCh384 build was used as human reference genome sequence. As the original 
coordinates of chromosome Y regions were defined on GRCh37 build [22], Lift Genome 
Annotations5 software was used to convert provided regional positions (Section 2.6) from 
GRCh37 to GRCh38 reference genome. For read mapping with Bowtie 2, ten computer 
cores were used in the developing process. According to the documentation, the searching 
for alignments is highly parallel and when aligning to a indexed human genome reference, 
increasing from one thread to eight threads will change the memory footprint by a few 
hundred megabytes [19]. Therefore, the parameters were chosen in a way to optimize sen-
sitivity over speed, but also take advantage of the use multiple cores. 
2.4 Data processing pipeline 
The developed pipeline has four main steps (Figure 3). 
 
Figure 3. Data processing pipeline. In step A, per NIPT sample FASTQ sequencing data 
files are concatenated. After A, in step B, sequence reads are aligned to a reference ge-
nome sequence. In step C, alignments are filtered by their mapping quality score and in D 
two different methods for estimating fetal fraction are applied and compared. In the final 
version, SeqFF and chromosome Y based method are used for estimating FF. 
                                                 
4 https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26  
5 https://genome.ucsc.edu/cgi-bin/hgLiftOver  
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First, the pipeline starts by concatenating per individual (sample FASTQ) files. This is 
necessary as each individual was sequenced on multiple sequencing lanes6 which led to 
sequencing reads being written into the multiple output files that are necessary to merge 
for further analysis. Second, pipeline continues with aligning sequencing reads to a refer-
ence genome (output is a SAM file). In this step, for each read the aligner must determine 
the read’s likely point of origin on reference genome [18]. 
Third, the alignments are filtered by their mapping quality score. Aligner cannot always 
determine the correct chromosomal region of every sequencing read with high confidence 
[18]. For example, in case of multiple alignment places there is no basis for preferring one 
alignment site over the others [18]. In this step, reads with low mapping score mapping 
equally well to several chromosomal regions will be removed. Finally, two different 
methods for estimating fetal fraction are applied. 
2.5 Aligned read filtering parameters 
SAMtools 1.8 [20] ‘view’ mode provides the option to specify threshold for filtering out 
aligned sequencing reads by their mapping (alignment) quality score (MAPQ). MAPQ is a 
non-negative integer 𝑄 =  −10 ⋅ log10 𝑝, where p is an estimate of the probability that the 
alignment does not correspond to the actual point of origin [18]. For example, if 𝑄 =  10, 
then there is at least 
1
10
 probability that read is truly originated elsewhere. if 𝑄 =  30, then 
the possibility is 
1
1000
, 𝑄 =  35 it is 
1
1000√10
 and with 𝑄 =  40 it is 
1
10000
. 
To investigate the effect of MAPQ at 25, 30, 35 and 40 on read count (in male and female 
foetus pregnancies) for chromosome Y provided regions (Section 2.6), each of this quality 
setting was tested (Figure 4).  
Figure 4 (remaining regions sum of counts between male and female pregnancies) illus-
trates the effect of MAPQ setting on read count. The highest read count is reduced from 
80,000 (A) to 50,000 (D). It also illustrates that there are chromosome Y regions where the 
alignments of reads count in female pregnancies is half or more of male pregnancies. This 
confirms that chromosome Y is not unique (even in some of those, assumingly unique 
regions). 
                                                 
6 Independent run in sequencing. 
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Figure 4. Read count distribution with MAPQ 25 (A), 30 (B), 35 (C) and 40 (D). The read 
counts for provided regions (coordinate in Table 1 in Section 2.6, page 19) are summed 
together between male and female pregnancies to see the mapping distribution. Although 
the distribution of the reads does not change, but the scale of read count is reduced from 
8,000 (A) to 5,000 (D) reads (note the arrows on the Y axis). 
If these read counts are normalized against the total length of the provided region length 
(separately for male and female foetus pregnancies) and summed separately between 
males and females (Figure 5), then inside female foetus pregnancy group the regions R4, 
R8, R9, R13, R23 and R24 have higher read count than in male pregnancy group. Such 
regions on chromosome Y, which have high presents of read counts from female foetus 
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pregnancies are subject to exclusion as they are not unique and will affect negatively the 
estimation of fetal fraction. 
 
Figure 5. Normalized read count distribution with MAPQ 25 (A), 30 (B), 35 (C) and 40 
(D). Read counts are normalized separately over female and male fetus pregnancies. It can 
be observed that regions (Table 1 in Section 2.6, page 19) such as R23 have proportionally 
higher female pregnancy aligned reads than in males. Regions, where the mapping-quality 
based filtering is most effective, have shown with arrows. 
Based on the previous analysis, MAPQ 35 was chosen as the final parameter. It is not too 
conservative as is MAPQ 40 which filters out over 2,000 aligned reads (Figure 4). Moreo-
ver, in terms of validity, MAPQ 35 cleans chromosome Y regions such as R17 or R18 
from aligned reads of female pregnancies (Figure 5). After applying MAPQ 35, there can 
be found 13 regions that have near zero level of aligned reads from female pregnancies 
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(Figure 5, arrows). This is not achievable with MAPQ of 25 or 30. Therefore, the option of 
MAPQ > 35 was used. 
In summary, applying filtering in general 1) enhances the accuracy of fetal fraction esti-
mation by cleaning chromosome Y regions by filtering out aligned sequences for which 
the point of origin cannot be determined with high confidence and 2) by doing this allows 
to keep some of the regions in analyses which otherwise might be discarded due to the 
high number of aligned sequences from female foetus pregnancies. 
2.6 Chromosome Y region selection 
Chromosome Y contains male-specific regions, which comprise 95% of the chromosome 
length [21]. Although chromosome Y is male-specific, it has several regions which exhibit 
> 99% sequence identity to the chromosome X. These regions are remnants of autosomes 
and repeated regions [21]. Therefore, most of the regions on chromosome Y are not 
unique – not only chromosome Y and male specific.  
2.6.1 Challenges in using chromosome Y for estimating FF 
The non-uniqueness proposes a challenge in estimating fetal fraction in NIPT samples 
based on chromosome Y. If chromosome Y would be unique, then any sequences mapped 
to the chromosome Y in male fetus pregnancies would be of fetal origin. This would allow 
direct application of the developed method (formula (4) in Section 2.8, page 25). 
When not considering the uniqueness, the direct application of the formula (4) (Section 
2.8, page 25) would lead to over- or underestimation of cffDNA due to the imprecision in 
read alignment process. Poznik and colleagues addressed the chromosome Y uniqueness 
issue by applying different filters for finding suitable regions [22]. They also made reliable 
chromosome Y regions available in their corresponding publication [22]. In the following 
work, regions provided by Poznik et al. were further evaluated and used to optimize 
chromosome Y based method (formula (4) in Section 2.8, page 25). Chromosome Y refer-
ence sequence is 59.36 Mbp from which the provided regions take up 17.6% of the chro-
mosome Y [22]. Regions on the closer observation are not dispersed over the chromosome 
Y (Figure 6).  
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Figure 6. Phenogram illustrating the distribution of unique (black stripes) regions on 
chromosome Y. Regions are rather close to each other and the distribution is not dispersed 
over the chromosome [22]. The average length of the region is 248,924 bp with minimum 
of 13,000 bp and maximum of 1,786,000 bp (Table 1). 
From Figure 6 it can be further concluded that the usage of reliable regions is necessary as 
the regions are not dispersed and make up only a marginal percentage of the entire chro-
mosome Y, therefore the usage of entire chromosome Y would have negative effect on the 
performance of the FF estimator on NIPT samples. 
2.6.2 Removal of regions with low read counts 
At this phase of the chromosome Y based method validation, 149 female and 170 male 
confirmed pregnancies were available for analysis (total of 319). The total count of 416 
Estonian NIPT samples, is the final number of samples that were processed. In the devel-
opment process the number varies as the sample collection and analysis was an iterative 
process. Most of the development phase was done with these 319 NIPT samples. 
To begin, the read counts per region were summed (Table 1). Minimum sum of the read 
counts per chromosome Y region was 916 and maximum 143,893. Median was 13,037. 
Based on the minimum, maximum and median value, all the regions that had lower read 
count than 10,000, were filtered out since with a low coverage sequencing assay these re-
gions would be less informative for cffDNA calculation and regions with low read counts 
would have direct effect on the accuracy of fetal fraction estimations with chromosome Y 
based method.  
  
Phenogram illustrating the provided regions on chromosome Y 
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Table 1. Detailed information of the regions. More precisely it presents notation used in 
Figure 7, start and end coordinates, length of the regions, 24 retained regions and sum of 
read counts across all individuals. 
Notation used 
in Figure 7 
Start  
position 
End posi-
tion 
Region 
length 
Retained Sum of read 
counts  
XR1 2786959 2805959 19000 
 
918 
XR2 2811959 3044959 233000 R1 11532 
XR3 6750959 6853958 102999 
 
7418 
XR4 6857959 7147959 290000 R2 20750 
XR5 7165959 7245959 80000 R3 15607 
XR6 7258959 7271959 13000 
 
1575 
XR7 7275959 7562959 287000 R4 92601 
XR8 7650959 8134959 484000 R5 28071 
XR9 8139958 9036959 897001 R6 52756 
XR10 9138391 9318391 180000 R7 13465 
XR11 9555391 9590391 35000 
 
2015 
XR12 9593391 9623391 30000 
 
1609 
XR13 9960391 10057391 97000 
 
5747 
XR14 11764294 11855294 91000 
 
4398 
XR15 11863294 12309273 445979 R8 114162 
XR16 12326273 12848075 521802 R9 98787 
XR17 12853075 13101086 248011 R10 13200 
XR18 13141086 13172099 31013 
 
1455 
XR19 13191099 13524120 333021 R11 16944 
XR20 13531120 13554120 23000 
 
1250 
XR21 13570120 13899120 329000 R12 37141 
XR22 13903120 13955120 52000 R13 39405 
XR23 14075120 15861120 1786000 R14 143893 
XR24 15919120 16144120 225000 R15 14921 
XR25 16442120 17052119 609999 R16 42812 
XR26 17076120 17270119 193999 R17 11307 
XR27 17279120 17371120 92000 
 
5469 
XR28 17381120 17439120 58000 
 
3221 
XR29 18887114 18988114 101000 
 
5931 
XR30 18996114 19583113 586999 R18 34947 
XR31 19584114 19666114 82000 
 
5095 
XR32 19681114 19780114 99000 
 
5377 
XR33 19782114 20048113 265999 R19 16659 
XR34 20379114 20466114 87000 
 
4753 
XR35 20483114 20994114 511000 R20 29842 
XR36 21080114 21475114 395000 R21 22294 
XR37 21584114 21736114 152000 R22 12874 
XR38 21811853 21845852 33999 
 
2728 
XR39 22226853 22239853 13000 
 
916 
XR40 22241853 22334852 92999 
 
5089 
XR41 26330853 26404853 74000 R23 67870 
XR42 26451853 26624852 172999 R24 47585 
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Figure 7. Sum of read counts over 319 samples from provided regions of chromosome Y. 
Regions names used on x-axis are presented in more detail in Table 1. 
This resulted in exclusion of 18 regions, retaining 24 regions for the analysis (Figure 7, 
Table 1).  
2.6.3 Secondary selection of regions for estimating FF 
The 24 regions selected in 2.6.2 Removal of regions with low read counts were not com-
pletely suitable as there are regions that have different contribution of read count from 
female foetus pregnancies (Figure 8). For example, region XR7 could be left out as it is 
non-unique (Figure 8). The effect of the region XR4, which has only some proportion of 
female fetus pregnancy reads, is unknown (Figure 8).  
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Figure 8. Normalized read count distribution in regions XR7 and XR4 (Table 1). Read 
counts are normalized against the total length of the provided region length (separately for 
male and female fetus pregnancies). 
One way to determine the effect of each region, would be to calculate fetal fraction with 
all possible combinations and compare the estimates of chromosome Y based method in 
case of female and male fetus pregnancies. Ideally, the fetal fraction in female pregnancies 
would be of 0%. Number of distinct combinations to calculate with 24 regions is 16 × 106 
cases7. It is not feasible to analyze all possible cases in reasonable time. 
To overcome this computational challenge, a table which aggregates the chromosome Y 
regions with their sum of read counts (separately in male and female fetus pregnancies) 
with ratio between these sums were created (Table 2). Table 2 is sorted by the ratio in as-
cending order. Sorting (Table 2) by the ratio supports differentiating regions by their 
uniqueness and therefore supports selecting regions for the final use. Ratio above one sug-
gests that region is dominated by the reads from female fetus pregnancies and have there-
fore less information and consequently priority for our analyses than regions which have 
ratio below one.  
  
                                                 
7 https://www.wolframalpha.com/input/?i=all+possible+combinations+of+24  
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Table 2. Chromosome Y regions sorted by the male to female ratio of sums of read counts. 
Region start position Males Females Ratio 
21584114 2.959743 0.006606 0.002232 
17076120 2.793317 0.009698 0.003472 
21080114 5.24871 0.028876 0.005502 
12853075 3.153792 0.017908 0.005678 
9138391 2.843008 0.019412 0.006828 
20483114 6.867333 0.050883 0.007409 
18996114 8.173656 0.064239 0.007859 
2811959 2.862409 0.023591 0.008242 
7650959 7.004222 0.064509 0.00921 
8139958 13.17753 0.194681 0.014774 
19782114 3.635995 0.070025 0.019259 
15919120 2.939929 0.126854 0.043149 
13191099 4.255738 0.310084 0.072863 
16442120 8.56994 1.290496 0.150584 
6857959 4.43507 0.768808 0.173347 
14075120 26.41177 7.104046 0.268973 
13570120 5.660408 4.023761 0.710861 
7165959 2.230995 3.425823 1.535558 
11863294 13.53649 23.34389 1.724516 
12326273 14.53354 25.20477 1.734248 
7275959 11.5016 24.16362 2.100892 
26451853 4.387126 9.938488 2.265375 
26330853 9.290916 25.97278 2.795503 
13903120 4.526755 12.77614 2.822362 
 
The relative information relevance of each region contribution with other regions by the 
order presented in Table 2 was investigated. Next, FF was calculated iteratively for differ-
ent combination of regions. Calculation started with the region with the smallest ratio 
(Table 2). In next iteration, region with higher ratio was added. Process continued for until 
all regions were added, e.g. each iteration added less informative region. For each set of 
these regions, the fetal fraction (formula (4) in Section 2.8, page 25) average and median 
for male and female fetus pregnancies was calculated and aggregated (Table 3).  
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Table 3. Fetal fraction calculation results from iterative leave-on-out region selection step. 
More precisely, in the column ‘order’ are the combination of regions used. For example, 
order 1 uses region 21584114, order 2 uses region 21584114 and 17076120, order 3 uses 
regions 21584114, 17076120, 21080114. The sequence follows as each next order uses all 
the previous regions added with one new region.  
Order Males average 
(%) 
Males median 
(%) 
Females average 
(%) 
Females median 
(%) 
1 19.94 16.63 0.97 0.97 
2 17.06 14.53 0.32 0.20 
3 15.19 12.79 0.13 0.08 
4 14.62 12.22 0.11 0.06 
5 14.85 12.30 0.11 0.05 
6 14.52 12.17 0.08 0.04 
7 14.46 12.04 0.06 0.03 
8 14.28 11.97 0.05 0.03 
9 14.35 12.07 0.05 0.03 
10 14.50 12.23 0.05 0.03 
11 14.46 12.17 0.05 0.03 
12 14.41 12.10 0.05 0.04 
13 14.30 11.89 0.06 0.05 
14 14.29 11.88 0.12 0.10 
15 14.35 11.96 0.15 0.13 
16 14.48 12.16 0.37 0.36 
17 14.58 12.26 0.49 0.48 
18 14.69 12.47 0.60 0.59 
19 15.41 13.11 1.33 1.31 
20 16.01 13.77 2.02 2.00 
21 16.65 14.54 2.67 2.65 
22 16.76 14.62 2.90 2.87 
23 17.48 15.37 3.63 3.58 
24 17.79 15.71 3.97 3.93 
 
Finally, for each of the combination of the regions, the distribution of fetal fractions was 
visualized with histograms for each order. This showed how well are the two groups sepa-
rable in terms of fetal fraction. These chromosome Y regions and corresponding histo-
grams are presented in the chapter Results. 
The previous steps described in this chapter are important as they made it possible to se-
lect reliable regions for estimating chromosome Y based fetal fraction in Estonian NIPT 
samples.  
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2.7 Computational workflow optimization 
Analyzing data in such a large scale presents multiple challenges. First, such analysis is 
not feasible on personal computer due to the amount of data (Section 2.2) and limited 
number of cores, storage and random-access memory. Everything had to be done in the 
high-performance computing center. All the calculations were performed on the High Per-
formance Computing Center of University of Tartu. 
Second, using computing center posed another task. Many of the necessary data pro-
cessing and analyzing tools existed as loadable modules in the computing centre, but they 
were not updated to the recent versions and differed between clusters. To overcome this, 
Anaconda (4.4.11) was used, which allowed to conveniently manage and use all the neces-
sary packages on the clusters were home directory was accessible.  
Third, the creation of temporally files is limited to the finite space of storage. In this case, 
total of 5 TB storage was available for use, but this was shared with other research pro-
jects, therefore usable space was under 5 TB. To address the limited storage, Linux piping 
was used. This did address the storage limitation but slowed the entire development since 
if there was need to change any parameter in the pipeline (Figure 3), the entire process had 
to be rerun as there was no history of temporary files.  
Finally, the analysis without parallel processing was expected to take usually one week in 
the computing center. Seven days of analysis hinders the development of the method since 
the pipeline had to be run multiple times. Since the analysis of single Estonian NIPT sam-
ple is completely independent of the analysis process of other NIPT samples, it was possi-
ble to create batches of samples that would be analyzed together. For example, nine batch-
es with each consisting of ≈ 50 samples could be run simultaneously (each as a separate 
job in the computing center). In this case, nine samples are processed in parallel. This re-
duced the running time to 24 hours. 
To conclude, the development of such method requires knowledge how to work with 
large-scale data, how to handle it, process it and analyze and therefore is in domain of 
computer science.  
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2.8 Chromosome Y based estimator 
To calculate fetal fraction, a method based on the chromosome Y was developed. 
Fetal fraction describes the proportion of the total cfDNA of fetal origin. Due to the fact 
that the 5 most frequently encountered chromosomal anomalies are trisomy in 13, 18, 21 
chromosome and monosomy in X and as fetal fraction can be thought as ratio between 
chromosome Y and autosomal chromosomes [23], the chromosomes 13, 18, 21 and X are 
excluded from calculations (formula (1)). 
𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡 ∶= {𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡 𝑖𝑛 𝑎𝑙𝑙 𝑐ℎ𝑟𝑜𝑚𝑜𝑠𝑜𝑚𝑒𝑠} ∖ {13,18,21, 𝑋, 𝑌} (1) 
Since autosomes are present in pairs, but chromosome Y is not and the differences in total 
read count and read count on chromosome Y need to be comparable, the autosomal read 
count is divided by 2 and with total length of all used chromosomes (formula (2)).  
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑐ℎ𝑟𝑜𝑚𝑠𝑜𝑚𝑒 𝑐𝑜𝑢𝑛𝑡 ≔
𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡
2   
𝐶𝐻𝑅 𝑇𝑂𝑇𝐴𝐿 𝐿𝐸𝑁𝐺𝑇𝐻
  (2) 
Chromosome Y read count also needs to be normalized, but as unique regions are used, 
chromosome Y read count is normalized against the chromosome Y unique regions total 
length (formula (3)). 
𝑛𝑜𝑟𝑚𝑌 =
𝑌 𝑐𝑜𝑢𝑛𝑡  
𝑌 𝐺𝑂𝑂𝐷 𝑅𝐸𝐺𝐼𝑂𝑁 𝐿𝐸𝑁𝐺𝑇𝐻
(3) 
Finally, the fetal fraction is defined as the ratio (formula (4)). 
𝑓𝑒𝑡𝑎𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
𝑛𝑜𝑟𝑚𝑌
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑐ℎ𝑟𝑜𝑚𝑜𝑠𝑜𝑚𝑒 𝑐𝑜𝑢𝑛𝑡
 ∗  100 (4) 
2.9 Applying SeqFF method 
Chromosome Y based method is not applicable to estimate fetal fraction on female fetus 
pregnancies and since the given data is not labeled with known fetal fraction, a method 
that would estimate fetal fractions for all Estonian NIPT samples would be highly prefera-
ble. If a proven method would correlate with chromosome Y based estimations and both 
methods’ results would align with literature, then two methods can be used to cross-
validate each other. The computational method that the author of the current study decided 
to apply in practice was SeqFF, as it: a) is a read count and machine learning based over 
the whole genome-based method; b) is technically applicable to our WGS-based NIPT 
data; c) is able to estimate FF for both male and female fetus pregnancies. This previously 
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published method cannot be directly used in Estonian NIPT as it was developed by us-
ing WGS data produced by slightly different laboratory procedure and its accuracy with 
Estonian low coverage WGS NIPT samples was not determined.  
SeqFF source code with a trained model was available under the supplementary materials 
with the published article [12]. The source code was adapted to accept input from Linux 
pipe and to return a value that would allow to use the whole script as a tool in the pipeline. 
Output would be these three estimates: the average of elastic net and WRSC (SeqFF), elas-
tic net and WRSC (Figure 9).  
Having three estimates as an output is more informative as in some cases elastic net failed 
to give an estimate due to some features (read counts in bins) being missing in some refer-
ence genome aligned samples’ files. The solution would have been filling the missing bins 
with values, but as WRSC did give realistic results, a filling of missing values not used 
(Figure 9). 
 
Figure 9. The estimates of the elastic net and WRSC correlate with Pearson correlation 
coefficient of 0.97 (266 samples, GRCh37). Therefore, if elastic net fails to produce esti-
mate, WRSC can still be used as a valid estimate.  
To adapt to SeqFF pipeline, the reference genome version in the alignment step had to be 
changed to GRCh37. Although our test analyses with GRCh38 did give realistic results, 
the method itself was trained by the authors using pre-built Bowtie 2 GRCh37 index [12]. 
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Therefore, the same index available at the Bowtie 2 website8 was used. As a result, SeqFF 
was integrated with the already existing (Figure 3) data processing pipeline.  
                                                 
8 http://bowtie-bio.sourceforge.net/bowtie2/index.shtml  
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 Results 
3.1 Chromosome Y based method 
As the first result of this thesis, the formula for estimating fetal fraction in male fetus 
pregnancies on Estonian NIPT samples was developed (formula (4) in Section 2.8, page 
25). Based on the section 2.6, 13 unique regions on chromosome Y in male fetus pregnan-
cies (order 13, Table 3 in Section 2.6, page 23) were determined. Compared to the usage 
of all sufficiently covered 24 regions (enough sequencing reads to calculate FF), selected 
13 regions effectively not only separate known male and female fetus pregnancies in terms 
of fetal fraction but also demonstrate FF close to 0% for all female fetus pregnancies, as 
expected in chromosome Y based FF calculations (Figure 10 and Figure 11).  
 
Figure 10. The usage of all the 24 regions showing that the distribution of male and female 
fetus fetal fractions is overlapping. To the left of the arrow are the female fetus pregnan-
cies and to the right are the male fetus pregnancies.  
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While in 24 region-based calculations the average and median of FF of female fetus preg-
nancies was 3.97% and 3.93%, respectively, the uniqueness of these 13 regions is further 
confirmed by the average of 0.06% and median of 0.05% of the fetal fraction of the female 
fetus pregnancies. Used male fetus pregnancies had average FF of 14.30% and median FF 
of 11.89% accordingly using chromosome Y based method (Table 3 in Section 2.6, page 
23). A study with 1,949 11-13 weeks’ pregnancies demonstrated a median fetal fraction of 
10% [24], which is close to the average of selected regions (difference of 1.89%). 
 
Figure 11. Histogram illustrating how 13 selected regions effectively distinguish female 
and male fetus pregnancies. There are two non-overlapping distributions of male and fe-
male fetus pregnancies. To the left of the arrow are the fetal fractions of the female fetus 
pregnancies and to the right are the fetal fractions of the male fetus pregnancies.  
Although, in the ordered list of all well-covered regions 12 first regions could also be used 
(Table 3 in Section 2.6, page 23), first 13 regions were selected as usage of these regions 
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resulted in FF estimates closer to the mean value of 10% in terms of fetal fraction that 
have been previously documented and reported by others [24].  
In conclusion, the combination of regions (13) was found which effectively separate 
male and female pregnancies and fetal fraction of female fetus pregnancy samples was 
near 0%, which is expected if calculations are done with chromosome Y. Therefore, the 13 
found chromosome Y regions with developed formula can be validated.  
3.2 Cross-validation of SeqFF and chromosome Y based methods 
The estimates of SeqFF and chromosome Y based solution on 151 Estonian NIPT male 
fetus pregnancies were compared. We determined that these two methods correlate highly, 
with the Pearson correlation of 0.96 (Figure 12). 
 
Figure 12. The correlation between chromosome Y based method and SeqFF in male 
pregnancies. Both methods demonstrate high correlation and therefore are usable in Esto-
nian population health setting. 
Median fetal fraction estimations of male pregnancies by SeqFF was 11%, which is 1% 
higher than 10% of median shown is one of the previously published studies [24]. Mini-
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mum estimated FF was 3% and maximum of 49%. Chromosome Y based method had the 
minimum value of 4% and maximum estimated FF of 41% (in male pregnancies). Median 
was 12%. Therefore, the minimum, maximum and median was between two methods very 
similar, the SeqFF being a bit more conservative. 
Based on the correlation and close median values to the values shown by Ashoor and the 
colleagues, the SeqFF and chromosome Y based method validated each other and could be 
used on Estonian male pregnancies. To investigate the estimate FF values on all the sam-
ple (including female fetus pregnancies), all the 416 NIPT samples were run through the 
pipeline. 
The distribution of the SeqFF estimates are shown in Figure 13. Out of 416 samples tested, 
the median of estimated fetal fraction was 13%, minimum 3% and maximum 49%. In gen-
eral, the median and range of estimated SeqFF-based FF values in Estonian NIPT samples 
align with literature [24]. 
 
Figure 13. Histogram that illustrates the SeqFF fetal fraction estimates on total of 416 
male and female pregnancies. 
In conclusion, the developed chromosome Y based method estimates align with the esti-
mates of SeqFF. Unlike chromosome Y based method, SeqFF is applicable on female 
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pregnancies. In the current study it was implemented and confirmed to give accurate fetal 
fraction estimates for Estonian low coverage (0.3–0.5×) WGS samples, therefore demon-
strating its applicability and accuracy for Estonian NIPT samples. 
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 Discussion 
The proportion of fetal cffDNA among maternal origin cell-free DNA is one of the key 
parameters in reliable and accurate NIPT analysis. Missing or non-accurate fetal fraction 
estimation can lead to inaccurate and consequently even false positive or negative results, 
which is not acceptable, especially in the context of precision medicine testing. Although 
multiple methods for determining the proportion of cfDNA exist, only one of those was 
(out-of-the-box) technically compatible with Estonian NIPT original laboratory protocol 
and type of data. Here we implement and validate SeqFF, a machine learning based com-
putational tool for estimating the proportion of cffDNA [12], with our published NIPTmer 
k-mer-based software [8] to detect fetal fraction in Estonian NIPT (NIPTIFY) samples for 
routine medical screening service.  
Although SeqFF is a published method, its performance on Estonian NIPT samples with 
original laboratory protocol was previously not determined. In one study, where 14,379 
low coverage whole genome sequenced diagnostic NIPT samples were analysed, it was 
found that best performance for fetal fraction determination is achieved with the chromo-
some Y based tool DEFRAG for male fetus pregnancies and SeqFF for female fetus preg-
nancies [16]. Their recommendation comes from the fact that although there was a con-
firmed high correlation between DEFRAG and SeqFF, but since SeqFF reported in two 
cases non-zero FF for 100% negative control samples, it was suggested to have further 
optimization [16]. In this thesis, the lack of negative control samples did not allow to ap-
ply SeqFF on 100% negative NIPT control samples. They also noted that on average Se-
qFF estimates were 2.34% less than DEFRAG [16]. This study saw similar trend that Se-
qFF estimates were about 1% more conservative on Estonian NIPT samples than chromo-
some Y based method estimates. In overall, they concluded that SeqFF gave the best per-
formance out of all non-chromosome Y based tools and is recommended for estimating FF 
for female fetus pregnancies [16]. To validate SeqFF on Estonian NIPT samples, the esti-
mations of cffDNA on sample were required. Since many of the available computational 
methods for estimating fetal fraction required data which were not available or laboratory 
protocol did not support, such as having only male fetus pregnancy samples sequenced 
(DEFRAG [5]) or having sequences with certain length, the author of the current study 
decided to develop a chromosome Y based method for estimating cffDNA. The developed 
chromosome Y method correlated with SeqFF and the final results were comparable with 
values shown in literature [24].  
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At the time of the writing, SeqFF is arguably the best available method for estimating fetal 
fraction in NIPTIFY test based on the following: (i) SeqFF is validated by the authors of 
the SeqFF [12], (ii) SeqFF has been used in many settings in multiple countries 
[15][16][17], and (iii) the estimates of SeqFF and chromosome Y based method on Esto-
nian NIPT samples are comparable with values shown in the literature [24]. 
For estimating cffDNA using chromosome Y based method, in total 13 unique regions 
(total of 4,705,030 bp, 7.93% of chromosome Y) on chromosome Y in male samples were 
determined. These regions could also be used in other applications which require high cer-
tainty of the origin of chromosome Y. Furthermore, for future research, the same analysis 
as was done in this thesis, could also be done for chromosome X – detecting regions in 
chromosome X that do not overlap with other chromosomes. Researches who are develop-
ing computational methods that rely on sequencing of sex chromosomes, could benefit of 
the existence of well-known unique regions. 
The limitation of the SeqFF is that while method itself is computationally inexpensive, it 
requires sequencing reads to be mapped to human reference genome [12], which is com-
putationally expensive process. Furthermore, as NIPTmer is k-mer based method (map-
ping-free) [8], incorporating mapping-based SeqFF, adds additional computational time 
for sample analysis.   
One possible solution to overcome of the mapping-based approach is to develop and apply 
alternative methods for aneuploidy detection and fetal fraction determination. Recently we 
published one of such promising method – Targeted Allele Counting by sequencing 
(TAC-seq) [25]. Instead of interrogating the whole genome (and also chromosomes that 
are virtually never in aneuploidy state), this method targets specific regions on the chro-
mosome(s) of interest to detect aneuploidies. In addition, it may simultaneously include 
loci that are most informative for fetal fraction estimation. Furthermore, indels (short in-
sertion or deletion variants) or variable methylation patterns difference between fetal- and 
maternal origin cell-free DNA can be possibly used. Such precise targeting would be more 
cost-effective than whole genome sequencing [25]. The regions for studying and selecting 
for such task could be derived from the SeqFF supplementary files, more precisely taking 
into the account the coefficients of elastic net for each bin on the genome [12]. This in 
theory could replace SeqFF in the pipeline with a method which has computationally less 
expensive requirements as SeqFF.  
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In conclusion, in the current study a chromosome Y based method for FF estimation was 
developed. Next, SeqFF method was implemented and validated with the developed 
chromosome Y based method. Furthermore, developed SeqFF computational workflow 
was successfully integrated into the NIPT service and is in daily use for estimating the 
proportion of cffDNA, enabling the estimation of cell-free fetal DNA fraction in male and 
female fetus pregnancies. All of the fetal fractions calculated for the scientific article man-
uscript ‘Creating basis for introducing NIPT in the Estonian public health setting’ used the 
pipeline developed in this thesis [6].  
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Summary 
The objective of this thesis was to find and validate a suitable computational methodology 
for estimating fetal fraction in low-coverage whole genome sequencing data for Estonian 
origin NIPT test. 
In the thesis, the existing methods for assessing fetal fraction were introduced. These 
methods included chromosome Y based method (limited only to male fetus pregnancies), 
SeqFF, a machine learning based method and methods that require more pre-requisites 
such as known parental genotypes. The working principles of each method with overview 
covering possible positive aspects and drawbacks were given. 
Thesis also presents in detail how large amount of data was analysed (at least 3.4 TB of 
data were processed) and how this work was carried out in the High Performance Compu-
ting Center of University of Tartu. Also, the origin of the samples used is presented. 
Thesis presents in detail all the required development steps for reaching a fully workable 
chromosome Y based computational method for estimating fetal fraction. Challenges ad-
dressed include the uniqueness of the chromosome Y, unknown actual fetal fraction and 
the amount of data that was needed to process in the High Performance Computing Centre. 
Thesis continues to validate the solution on Estonian NIPT samples. For that, chromosome 
Y based method estimates were compared to the values documented in the pertaining liter-
ature. Next, the current study presents, how a machine learning based method (SeqFF) is 
set up and used to estimate the fetal fraction for all the samples. It was investigated and as 
a result SeqFF correlated with chromosome Y based method (Pearson correlation of 0.96). 
Thesis ends with discussion. In the future, it might be possible to use SeqFF trained model 
coefficients to find detect and use regions specific to fetal fraction in more precise setting.  
As a result of this thesis, SeqFF was found and calibrated on Estonian NIPT samples with 
the developed chromosome Y based method and integrated into the NIPTIFY computa-
tional pipeline for the reduction of false positive results. Do date, SeqFF based computa-
tional pipeline is a part of NIPTIFY medical service that is available in more than 20 clin-
ics in Estonia.   
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